[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200702612A1 - Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт - Google Patents

Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт

Info

Publication number
EA200702612A1
EA200702612A1 EA200702612A EA200702612A EA200702612A1 EA 200702612 A1 EA200702612 A1 EA 200702612A1 EA 200702612 A EA200702612 A EA 200702612A EA 200702612 A EA200702612 A EA 200702612A EA 200702612 A1 EA200702612 A1 EA 200702612A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
present
agonists
benzimidazozolkarboxamide
receptors
Prior art date
Application number
EA200702612A
Other languages
English (en)
Other versions
EA013240B1 (ru
Inventor
Роберт Мюррей Маккиннелл
Роланд Гендрон
Лань Дзян
Сеок-Ки Чой
Дэниэл Д. Лонг
Пол Р. Фазери
Дэниел Маркесс
Шон М. Далзил
Кирстен М. Физакерли
Original Assignee
Тереванс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200702612(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тереванс, Инк. filed Critical Тереванс, Инк.
Publication of EA200702612A1 publication Critical patent/EA200702612A1/ru
Publication of EA013240B1 publication Critical patent/EA013240B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к бензимидазолкарбоксамидным агонистам рецептора 5-НТ, являющимся соединениями формулы (I)где Rи Х являются такими, как определено в описании, или к их фармацевтически приемлемой соли, или сольвату, или стереоизомеру. Настоящее изобретение также относится к фармацевтическим композициям, содержащим такие соединения, к способам применения таких соединений для лечения заболеваний, связанных с активностью рецептора 5-НТ, и к способам и промежуточным продуктам, полезным для получения таких соединений. Настоящее изобретение дополнительно относится к кристаллическим формам соединений формулы (I).
EA200702612A 2005-05-25 2006-05-24 Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт EA013240B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68447805P 2005-05-25 2005-05-25
US68446605P 2005-05-25 2005-05-25
US74841505P 2005-12-08 2005-12-08
PCT/US2006/020085 WO2006127815A2 (en) 2005-05-25 2006-05-24 Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Publications (2)

Publication Number Publication Date
EA200702612A1 true EA200702612A1 (ru) 2008-06-30
EA013240B1 EA013240B1 (ru) 2010-04-30

Family

ID=37452788

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702612A EA013240B1 (ru) 2005-05-25 2006-05-24 Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт

Country Status (27)

Country Link
US (10) US8143279B2 (ru)
EP (1) EP1899324B1 (ru)
JP (2) JP5072111B2 (ru)
KR (1) KR101333280B1 (ru)
AR (1) AR057327A1 (ru)
AT (1) ATE535523T1 (ru)
AU (1) AU2006250009B2 (ru)
BR (1) BRPI0611202C1 (ru)
CA (1) CA2607280C (ru)
CY (1) CY1112366T1 (ru)
DK (1) DK1899324T3 (ru)
EA (1) EA013240B1 (ru)
ES (1) ES2376115T3 (ru)
HK (1) HK1110980A1 (ru)
HR (1) HRP20120108T2 (ru)
IL (1) IL186883A (ru)
MA (1) MA29541B1 (ru)
MX (1) MX2007014762A (ru)
MY (1) MY147756A (ru)
NO (1) NO339658B1 (ru)
NZ (1) NZ563068A (ru)
PE (1) PE20061446A1 (ru)
PL (1) PL1899324T3 (ru)
PT (1) PT1899324E (ru)
SI (1) SI1899324T1 (ru)
TW (1) TWI388555B (ru)
WO (1) WO2006127815A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004268840B9 (en) * 2003-09-03 2011-02-03 Pfizer Inc. Benzimidazolone compounds having 5-HT4 receptor agonistic activity
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
JP2012521428A (ja) 2009-03-23 2012-09-13 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛治療用のｐ２ｘ３受容体アンタゴニスト
NO2419104T3 (ru) * 2009-04-13 2018-04-07
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
EP3031802A4 (en) * 2013-08-09 2017-07-12 Santen Pharmaceutical Co., Ltd Production method for 3, 3-dimethyl-3, 4-dihydro-1h-quinoxaline-2-one derivative and intermediate for said production method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
JPH111472A (ja) 1996-04-30 1999-01-06 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体及びそれを含有する医薬組成物
HUP0101511A3 (en) 1998-04-28 2002-12-28 Dainippon Pharmaceutical Co 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
TR200200972T2 (tr) 1998-11-03 2002-07-22 Basf Aktiengesellschaft İkameli 2-fenilbenzimidazoller, üretimleri ve kullanımları
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
JP2001122784A (ja) 1999-10-27 2001-05-08 Dainippon Pharmaceut Co Ltd １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬
EP1296684A2 (en) * 2000-06-07 2003-04-02 ARYx Therapeutics Treatment of gastroesophageal reflux disease using piperidine derivatives
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
PT1546134E (pt) 2002-08-05 2007-08-10 Lilly Co Eli ''arilbenzodiazepinas substituídas com piperazina''
JP2006502180A (ja) 2002-09-20 2006-01-19 ファイザー株式会社 ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
JP2004277318A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
JP2004277320A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １，４−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物
AU2004268840B9 (en) 2003-09-03 2011-02-03 Pfizer Inc. Benzimidazolone compounds having 5-HT4 receptor agonistic activity
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7256294B2 (en) 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound

Also Published As

Publication number Publication date
NO339658B1 (no) 2017-01-16
PL1899324T3 (pl) 2012-04-30
US10233172B2 (en) 2019-03-19
US20130273568A1 (en) 2013-10-17
JP2008542281A (ja) 2008-11-27
HRP20120108T2 (hr) 2012-03-31
MY147756A (en) 2013-01-15
US20170081313A1 (en) 2017-03-23
AR057327A1 (es) 2007-11-28
KR101333280B1 (ko) 2013-11-28
US11254655B2 (en) 2022-02-22
IL186883A0 (en) 2008-02-09
US8143279B2 (en) 2012-03-27
JP2012197322A (ja) 2012-10-18
ATE535523T1 (de) 2011-12-15
BRPI0611202B1 (pt) 2019-09-24
JP5072111B2 (ja) 2012-11-14
EA013240B1 (ru) 2010-04-30
DK1899324T3 (da) 2012-02-13
US20180237420A1 (en) 2018-08-23
SI1899324T1 (sl) 2012-03-30
NZ563068A (en) 2011-01-28
US10696656B2 (en) 2020-06-30
EP1899324A2 (en) 2008-03-19
MA29541B1 (fr) 2008-06-02
AU2006250009A1 (en) 2006-11-30
KR20080021045A (ko) 2008-03-06
US20090209582A1 (en) 2009-08-20
ES2376115T3 (es) 2012-03-09
MX2007014762A (es) 2008-02-14
WO2006127815A3 (en) 2007-08-02
US7759363B2 (en) 2010-07-20
HRP20120108T1 (en) 2012-02-29
PT1899324E (pt) 2012-01-24
HK1110980A1 (en) 2008-07-25
CA2607280A1 (en) 2006-11-30
WO2006127815A2 (en) 2006-11-30
US8377964B2 (en) 2013-02-19
US20190152951A1 (en) 2019-05-23
CY1112366T1 (el) 2015-12-09
US20200283408A1 (en) 2020-09-10
US20220274957A1 (en) 2022-09-01
BRPI0611202A2 (pt) 2010-08-24
US20060270652A1 (en) 2006-11-30
TWI388555B (zh) 2013-03-11
PE20061446A1 (es) 2007-01-16
CA2607280C (en) 2013-09-17
EP1899324B1 (en) 2011-11-30
US9975877B2 (en) 2018-05-22
AU2006250009B2 (en) 2012-03-08
TW200716607A (en) 2007-05-01
US20150183761A1 (en) 2015-07-02
US9428489B2 (en) 2016-08-30
US20100249186A1 (en) 2010-09-30
BRPI0611202B8 (pt) 2019-09-24
BRPI0611202C1 (pt) 2021-05-25
NO20076481L (no) 2007-12-17
IL186883A (en) 2013-03-24

Similar Documents

Publication Publication Date Title
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
EA200701705A1 (ru) Антагонисты рецепторы глюкагона, получение и терапевтическое применение
NO20073182L (no) Indazol-karboksamidforbindelser
MY155036A (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
EA200800540A1 (ru) Карбоксамидные производные в качестве антагонистов мускариновых рецепторов
DE602006019595D1 (de) Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
TW200800981A (en) 8-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonists
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) Chinolinon-carboxamid-verbindungen
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
DE602004024383D1 (de) Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists
EA200701867A1 (ru) Хинолиноновые соединения в качестве агонистов рецептора 5-ht
EA200970432A1 (ru) 8-сульфонил-1,3,4,8-тетрагидро-2н-[1,4]оксазепино[6,7-e] индольные производные и их использование в качестве 5-нт6 рецепторных лигандов
MXPA05013256A (es) Derivados de 1-(alquilaminoalquil-pirolidin-/piperidinil) -2,2-difenilacetamida como antagonistas de receptores muscarinicos.
EA200970426A1 (ru) Селективный агонист tr-бета 1
ATE525360T1 (de) Neuartige imidazolinylmethyl-aryl-sulfonamide
MY143574A (en) Carbamate compounds as 5-ht4 receptor agonists
ATE531697T1 (de) Neuartige imidazolinylmethyl-aryl-sulfonamide
UA89846C2 (ru) Производные карбоксамида как антагонисты мускариновых рецепторов

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment